Annexure 2: Seminar Schedule

Day One: 20th October, 2016

Time

Theme/Session

Speakers & Chairs

9:00-9:30Registration
9:30-10:00Welcome, Objectives of the Seminar and Participant Self-IntroductionsOrganisers
WelcomeDr J K Das, Director, NIHFW
10:00-10:15Key Words: Mr C.K Mishra, Secretary Health, MOHFW - TBC

10:15-10:30

Tea

SESSION I


10:30-12:45

Present Status Of Children’s Health and Vaccination

Chair: Dr. Soumya Swaminathan (DG, ICMR) - TBC

10:30-10:45Child Health in India: Current Status and GoalsDr. A. P. Dubey
10:45-11:00Journey of UIP in IndiaDr. Chandrakant Lahariya - TBC
11:00-11:15Burden of Disease & Effectiveness of Vaccines in the UIPDr. T Jacob John
11:15-11:30Prioritisation of New Vaccines in Government PolicyDr. Rakhal Gaitonde
11:30-12:45Discussion

12:45-13:45

Lunch

SESSION II


13:30-15:15

Prioritisation of interventions for disease prevention

Chair: Mr. Manoj Jhalani (JS, MOHFW) and Dr. Vandana Prasad

13:45-14:00Role of vaccine in disease preventionProf. Vinod Paul
14:00-14:15Effectiveness and benefits of investment to improve determinants of healthDr. Rakesh Lodha
14:15-14:30Balancing Priorities in Policy MakingDr. Madhavi Y.
14:30-15:15Discussion

15:15-15:30

Tea

SESSION III


15:30-17:00

Inclusion of new vaccine in the UIP: How effective are new vaccines?

Chair: Dr. Anant Phadke

15:30-15:45Effectiveness of vaccines: Rota Virus and Pneumococcal vaccinesDr. Gagandeep Kang
15:45-16:00Effectiveness of vaccines: HPV and Other VaccinesDr. Vineeta Bal
16:00-17:30Discussion

Day Two: 21st October, 2016

SESSION IV


9:30-10:45

Inclusion of New Vaccine in the UPI: Risk Assessment and safety of vaccine

Chair: Prof. Imrana Qadeer

9:30-9:45How Safe are New Vaccines?Dr. S. K. Mittal
9:45-10:00Challenges and Investigations of Adverse Events Following Vaccination (AEFI)Dr. Jacob Puliyel
10:00-10:15AEFI Causality Assessment ProtocolDr. L Machado (WHO)
10:15-10:45Discussion

10:45-11:00

Tea

SESSION V


11:00-12:15

Ethics and Regulations

Chair: Dr. Amar Jesani

11:00-11:15Data Transparency: Importance of Public Availability of Anonymised Raw DataMr. S. Srinivasan
11:15-11:30Compensation For Injury and Deaths in VaccinationMs. Sarojini N.
11:30-11:45Rights, Informed Consent in VaccinationMs. Veena Johari
11:45-12:15Discussion

12:15-13:00

Lunch

SESSION VI


13:00-14:45

Inclusion of new vaccine in the UIP: Cost effectiveness & Financial issues

Chair: Dr. Amit Sengupta

13:00-13:30Economic Evaluation of Vaccination ProgrammesProf. VR Muraleedharan, Dr. Rakhal Gaitonde
13:30-13:45Implications of Cost on VaccinesDr. Ravi Duggal
13:45-14:00Invited Comment: Criteria for Cost- effectiveness of New VaccinesProf. Indrani Gupta
14:00-14:45Discussion

14:45-15:15

Tea

SESSION VII


15:15-16:30

Inclusion of new vaccine in the UIP: Health System Preparedness

Chair: Prof. Mohan Rao

15:15-15:30How Robust is Public Surveillance System to Monitor AEFI?Dr. Jyoti Jain
15:30-15:45How Prepared is the System to Deliver Increasing Number of Vaccines?Dr. M. K. Aggarwal
15:30-15:45Discussion

15:30-15:45

Summarising and closing remarks

Dr. Amit Sengupta, Dr. Yogesh Jain and Ms. Sarojini N

Highlights from the Seminar Sessions

Session I: Present Status of Children’s Health and Vaccination
Session II: Prioritisation of Interventions for Disease Prevention
Session III: Inclusion of new vaccine in the UIP: How effective are new vaccines?
Session IV: Inclusion of new vaccine in the UIP: Risk assessment and safety of vaccine
Session V: Ethics and Regulations
Session VI: Inclusion of new vaccine in the UIP: Cost effectiveness and Financial issues
Session VII: Inclusion of New Vaccines in the UIP: Health System Preparedness
Recommendations

Annexures

Annexure 1: Background Note of the Seminar
Annexure 2: Seminar Schedule
Annexure 3: Organisers of the Seminar
Annexure 4: List of Participants

Back to the Report

Comments are closed.